NOT-TR-19-022: Notice of Participation of the National Center for Advancing Translational Sciences (NCATS) in RFA-HL-20-014 - "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"

Notice of Participation of the National Center for Advancing Translational Sciences (NCATS) in RFA-HL-20-014 - "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"

Notice Number: NOT-TR-19-022

Key Dates
Release Date: June 6, 2019

Related Announcements
RFA-HL-20-014

Issued by
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to inform potential applicants that the National Center for Translational Sciences (NCATS) will participate, effective immediately, in RFA-HL-20-014 - "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"

The following changes and updates are made to RFA-HL-20-014 (shown in italics) to reflect NCATS participation in this FOA.

Part 1. Overview Information

Component of Participating Organizations

National Heart, Lung and Blood Institute (NHLBI)

National Center for Advanced of Translational Sciences (NCATS)

Catalog of Federal Domestic Assistance (CFDA) Numbers

93.837, 93.838, 93.839, 93.840, 93.233, 93.350

Inquiries

Please direct all inquiries to:

Tiina Urv, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301.827.2746
Email: [email protected]